Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
Cyramza | Ramucirumab | Cancelled | ||||
Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |